SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERα transcriptional activity

Cancer Research

Volumn 73, Issue 1, 2013, Pages 246-255

  Zhang, Luduo ^a   Gong, Chun ^a   Lau, Samantha L Y ^a   Yang, Nan ^a   Wong, Oscar G W ^a   Cheung, Annie N Y ^a   Tsang, Janice W H ^a   Chan, Kelvin Y K ^a,b   Khoo, Ui Soon ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b TSAN YUK HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; NUCLEAR RECEPTOR COREPRESSOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG SENSITIVITY; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NCOR2 GENE; PREDICTION; PRIORITY JOURNAL; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; TRIPLE NEGATIVE BREAST CANCER;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NUCLEAR RECEPTOR CO-REPRESSOR 2; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84872002796     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2241     Document Type: Article

References (32)

1. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002;296:1642-4.
2. Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
3. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001;53:25-71.
4. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9:631-43.
5. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 2008;14:1744-52.
6. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005;23:732-40.
7. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, et al. Predicting prognosis using molecular profiling in estrogen recep-tor-positive breast cancer treated with tamoxifen. BMC Genomics 2008;9:239.
8. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-16.
9. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
10. Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, et al. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Res 2008;10:R88.
11. Fackenthal JD, Godley LA. Aberrant RNA splicing and its functional consequences in cancer cells. Dis Model Mech 2008;1:37-42.
12. Brinkman BM. Splice variants as cancer biomarkers. Clin Biochem 2004;37:584-94.
13. Zhang C, Li HR, Fan JB, Wang-Rodriguez J, Downs T, Fu XD, et al. Pro filing alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics 2006;7:202.
14. Venables JP, Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Koh C, et al. Identi fication of alternative splicing markers for breast cancer. Cancer Res 2008;68:9525-31.
15. Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Gervais-Bird J, Madden R, et al. Multiple alternative splicing markers for ovarian cancer. Cancer Res 2008;68:657-63.
16. Wong LJ, Dai P, Lu JF, Lou MA, Clarke R, Nazarov V. AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines. BMC cancer 2006;6:111.
17. Heard J, Kaufmann W, Guan X. A novel method for large tree visualization. Bioinformatics 2009;25:557-8.
18. Saldanha AJ. Java Treeview-extensible visualization of microarray data. Bioinformatics 2004;20:3246-8.
19. Chen J, Gomes AR, Monteiro LJ, Wong SY, Wu LH, Ng TT, et al. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PLoS ONE 2010;5:e12293.
20. Peterson TJ, Karmakar S, Pace MC, Gao T, Smith CL. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) core-pressor is required for full estrogen receptor alpha transcriptional activity. Mol Cell Biol 2007;27:5933-48.
21. Cheng X, Kao HY. G protein pathway suppressor 2 (GPS2) is a transcriptional corepressor important for estrogen receptor alpha-mediated transcriptional regulation. J Biol Chem 2009;284:36395-404.
22. Romano A, Adriaens M, Kuenen S, Delvoux B, Dunselman G, Evelo C, et al. Identification of novel ER-alpha target genes in breast cancer cells: gene- and cell-selective co-regulator recruitment at target promoters determines the response to 17beta-estradiol and tamoxifen. Mol Cell Endocrinol 2010;314:90-100.
23. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995;377:454-7.
24. Dobrzycka KM, Townson SM, Jiang S, Oesterreich S. Estrogen receptor corepressors - a role in human breast cancer? Endocr Relat Cancer 2003;10:517-36.
25. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997;11:657-66.
26. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 1998;95:2920-5.
27. Varlakhanova N, Snyder C, Jose S, Hahm JB, Privalsky ML. Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain. Mol Cell Biol 2010;30:1434-45.
28. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000;103:843-52.
29. Liu XF, Bagchi MK. Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo . J Biol Chem 2004;279:15050-8.
30. Kaasa SO, Peterson T, Morris EK, Thompson WC. Statistical inference and forensic evidence: evaluating a bullet lead match. Law Hum Behav 2007;31:433-47.
31. Zhang XM, Chang Q, Zeng L, Gu J, Brown S, Basch RS. TBLR1 regulates the expression of nuclear hormone receptor co-repressors. BMC Cell Biol 2006;7:31.
32. Hoberg JE, Popko AE, Ramsey CS, Mayo MW. IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol Cell Biol 2006;26:457-71.